From Discovery to Preclinical Validation of a Novel BRD4 Degrader, MT-4561
4:45 pm - Wednesday 10th June 2026
- Leveraging a proprietary TPD platform to rapidly discover potent degraders targeting BRD4
- Discussing lead optimization to achieve durable anti-tumor efficacy in diverse cancer models and patient-derived cells
- Presenting preclinical pharmacology insights to support clinical development
